Global trends in research of melanoma differentiation-associated gene 5: a bibliometric analysis from 2002 to 2022.

Bibliometrics Dermatomyositis Innate immunity MDA5

Journal

Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469

Informations de publication

Date de publication:
06 Jan 2024
Historique:
received: 19 05 2023
accepted: 16 12 2023
revised: 11 12 2023
medline: 6 1 2024
pubmed: 6 1 2024
entrez: 5 1 2024
Statut: aheadofprint

Résumé

Melanoma differentiation-associated gene 5 (MDA5), as a cytoplasmic sensor for viral double-stranded RNAs, has received increasing attention in recent years. Although considerable headway has been made on the functional role of MDA5 in antiviral immunity and autoimmune disease, the available literature is insufficient to assess the vast field. This study performed a bibliometric analysis to investigate current hotspots in the global scientific output of MDA5 over the past two decades. Related publications and recorded information from 2002 to 2022 in the Web of Science Core Collection (WoSCC) database were retrieved. VOSviewer and CiteSpace were used for quantitative evaluation and visualization. A total of 2267 original articles and reviews were obtained, and the annual number of publications related to MDA5 was increasing rapidly. China has published the most papers, while the USA was the most influential country with the most citations and the highest H-index. The Chinese Academy of Sciences, the United States Department of Health and Human Services, and the Journal of Virology were the most prolific research affiliation, funding source, and journal, respectively. Fujita T (Kyoto University) was the most productive author with the highest H-index and had close cooperation with Kato H and Yoneyama M. The keywords "RIG-I," "MDA5," "innate immunity," "double-stranded-RNA," and "recognition" had the highest frequency, while "dermatomyositis" as well as "autoantibody" seemed to be the emerging hotspots. This study comprehensively demonstrated the research frontiers of MDA5 and will provide a useful resource for scholars to conduct future decisions. We conducted the first in-depth survey of the research frontiers on melanoma differentiation-associated gene 5 (MDA5) over the past two decades via bibliometric analysis. We found that many early breakthroughs have been made in the mechanism of MDA5-mediated antiviral immune responses, and the role of MDA5 in autoimmune and autoinflammatory diseases has raised the recent concern. We identified that the virus infection-associated pathogenesis and effective therapeutic strategy of anti-MDA5 antibody-positive dermatomyositis will remain the hotspots in the future.

Sections du résumé

BACKGROUND BACKGROUND
Melanoma differentiation-associated gene 5 (MDA5), as a cytoplasmic sensor for viral double-stranded RNAs, has received increasing attention in recent years. Although considerable headway has been made on the functional role of MDA5 in antiviral immunity and autoimmune disease, the available literature is insufficient to assess the vast field.
METHODS METHODS
This study performed a bibliometric analysis to investigate current hotspots in the global scientific output of MDA5 over the past two decades. Related publications and recorded information from 2002 to 2022 in the Web of Science Core Collection (WoSCC) database were retrieved. VOSviewer and CiteSpace were used for quantitative evaluation and visualization.
RESULTS RESULTS
A total of 2267 original articles and reviews were obtained, and the annual number of publications related to MDA5 was increasing rapidly. China has published the most papers, while the USA was the most influential country with the most citations and the highest H-index. The Chinese Academy of Sciences, the United States Department of Health and Human Services, and the Journal of Virology were the most prolific research affiliation, funding source, and journal, respectively. Fujita T (Kyoto University) was the most productive author with the highest H-index and had close cooperation with Kato H and Yoneyama M. The keywords "RIG-I," "MDA5," "innate immunity," "double-stranded-RNA," and "recognition" had the highest frequency, while "dermatomyositis" as well as "autoantibody" seemed to be the emerging hotspots.
CONCLUSION CONCLUSIONS
This study comprehensively demonstrated the research frontiers of MDA5 and will provide a useful resource for scholars to conduct future decisions.
KEY POINTS CONCLUSIONS
We conducted the first in-depth survey of the research frontiers on melanoma differentiation-associated gene 5 (MDA5) over the past two decades via bibliometric analysis. We found that many early breakthroughs have been made in the mechanism of MDA5-mediated antiviral immune responses, and the role of MDA5 in autoimmune and autoinflammatory diseases has raised the recent concern. We identified that the virus infection-associated pathogenesis and effective therapeutic strategy of anti-MDA5 antibody-positive dermatomyositis will remain the hotspots in the future.

Identifiants

pubmed: 38182800
doi: 10.1007/s10067-023-06851-x
pii: 10.1007/s10067-023-06851-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Références

Kang DC, Gopalkrishnan RV, Wu Q et al (2002) mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci USA 99:637–642. https://doi.org/10.1073/pnas.022637199
doi: 10.1073/pnas.022637199 pubmed: 11805321 pmcid: 117358
Kang DC, Gopalkrishnan RV, Lin L et al (2004) Expression analysis and genomic characterization of human melanoma differentiation associated gene-5, mda-5: a novel type I interferon-responsive apoptosis-inducing gene. Oncogene 23:1789–1800. https://doi.org/10.1038/sj.onc.1207300
doi: 10.1038/sj.onc.1207300 pubmed: 14676839
Andrejeva J, Childs KS, Young DF et al (2004) The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci USA 101:17264–17269. https://doi.org/10.1073/pnas.0407639101
doi: 10.1073/pnas.0407639101 pubmed: 15563593 pmcid: 535396
Gitlin L, Barchet W, Gilfillan S et al (2006) Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci USA 103:8459–8464. https://doi.org/10.1073/pnas.0603082103
doi: 10.1073/pnas.0603082103 pubmed: 16714379 pmcid: 1464000
Cunninghame Graham DS, Morris DL, Bhangale TR et al (2011) Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet 7:e1002341. https://doi.org/10.1371/journal.pgen.1002341
doi: 10.1371/journal.pgen.1002341 pubmed: 22046141 pmcid: 3203198
Crow YJ, Manel N (2015) Aicardi-Goutieres syndrome and the type I interferonopathies. Nat Rev Immunol 15:429–440. https://doi.org/10.1038/nri3850
doi: 10.1038/nri3850 pubmed: 26052098
Smyth DJ, Cooper JD, Bailey R et al (2006) A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 38:617–619. https://doi.org/10.1038/ng1800
doi: 10.1038/ng1800 pubmed: 16699517
Chiappinelli KB, Strissel PL, Desrichard A et al (2017) Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 169:361. https://doi.org/10.1016/j.cell.2017.03.036
doi: 10.1016/j.cell.2017.03.036 pubmed: 28388418
Xu L, Wang L, Lv C et al (2021) Anti-MDA-5-positive dermatomyositis associated rapidly progressive interstitial lung disease, a virus-triggered autoimmune-like symptom? Rheumatology 60:4428–4429. https://doi.org/10.1093/rheumatology/keab224
doi: 10.1093/rheumatology/keab224 pubmed: 33752230
Gono T, Okazaki Y, Kuwana M (2022) Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease. Rheumatology (Oxford) 61:806–814. https://doi.org/10.1093/rheumatology/keab371
doi: 10.1093/rheumatology/keab371 pubmed: 33890985
Wu F, Gao J, Kang J et al (2022) Knowledge mapping of exosomes in autoimmune diseases: a bibliometric analysis (2002-2021). Front Immunol 13:939433. https://doi.org/10.3389/fimmu.2022.939433
doi: 10.3389/fimmu.2022.939433 pubmed: 35935932 pmcid: 9353180
Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174
doi: 10.2307/2529310 pubmed: 843571
Synnestvedt MB, Chen C, Holmes JH (2005) CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annu Symp Proc 2005:724–728
pubmed: 16779135 pmcid: 1560567
van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84:523–538. https://doi.org/10.1007/s11192-009-0146-3
doi: 10.1007/s11192-009-0146-3 pubmed: 20585380
Hamel R, Dejarnac O, Wichit S et al (2015) Biology of Zika virus infection in human skin cells. J Virol 89:8880–8896. https://doi.org/10.1128/JVI.00354-15
doi: 10.1128/JVI.00354-15 pubmed: 26085147 pmcid: 4524089
Lei X, Dong X, Ma R et al (2020) Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun 11:3810. https://doi.org/10.1038/s41467-020-17665-9
doi: 10.1038/s41467-020-17665-9 pubmed: 32733001 pmcid: 7392898
Soy M, Keser G, Atagunduz P et al (2020) Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 39:2085–2094. https://doi.org/10.1007/s10067-020-05190-5
doi: 10.1007/s10067-020-05190-5 pubmed: 32474885 pmcid: 7260446
Wu J, Chen ZJ (2014) Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol 32:461–488. https://doi.org/10.1146/annurev-immunol-032713-120156
doi: 10.1146/annurev-immunol-032713-120156 pubmed: 24655297
Liddicoat BJ, Piskol R, Chalk AM et al (2015) RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science 349:1115–1120. https://doi.org/10.1126/science.aac7049
doi: 10.1126/science.aac7049 pubmed: 26275108 pmcid: 5444807
Goubau D, Schlee M, Deddouche S et al (2014) Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5′-diphosphates. Nature 514:372–375. https://doi.org/10.1038/nature13590
doi: 10.1038/nature13590 pubmed: 25119032 pmcid: 4201573
Yoneyama M, Onomoto K, Jogi M et al (2015) Viral RNA detection by RIG-I-like receptors. Curr Opin Immunol 32:48–53. https://doi.org/10.1016/j.coi.2014.12.012
doi: 10.1016/j.coi.2014.12.012 pubmed: 25594890
Tan XJ, Sun LJ, Chen JQ et al (2018) Detection of microbial infections through innate immune sensing of nucleic acids. Annu Rev Microbiol 72(72):447–478. https://doi.org/10.1146/annurev-micro-102215-095605
doi: 10.1146/annurev-micro-102215-095605 pubmed: 30200854
Roulois D, Loo Yau H, Singhania R et al (2015) DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162:961–973. https://doi.org/10.1016/j.cell.2015.07.056
doi: 10.1016/j.cell.2015.07.056 pubmed: 26317465 pmcid: 4843502
Ishizuka JJ, Manguso RT, Cheruiyot CK et al (2019) Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 565:43–48. https://doi.org/10.1038/s41586-018-0768-9
doi: 10.1038/s41586-018-0768-9 pubmed: 30559380
Kato H, Takeuchi O, Sato S et al (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101–105. https://doi.org/10.1038/nature04734
doi: 10.1038/nature04734 pubmed: 16625202
Kato H, Takeuchi O, Mikamo-Satoh E et al (2008) Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 205:1601–1610. https://doi.org/10.1084/jem.20080091
doi: 10.1084/jem.20080091 pubmed: 18591409 pmcid: 2442638
Kawai T, Takahashi K, Sato S et al (2005) IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 6:981–988. https://doi.org/10.1038/ni1243
doi: 10.1038/ni1243 pubmed: 16127453
Meylan E, Curran J, Hofmann K et al (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:1167–1172. https://doi.org/10.1038/nature04193
doi: 10.1038/nature04193 pubmed: 16177806
Hornung V, Ellegast J, Kim S et al (2006) 5′-Triphosphate RNA is the ligand for RIG-I. Science 314:994–997. https://doi.org/10.1126/science.1132505
doi: 10.1126/science.1132505 pubmed: 17038590
Hornung V, Ablasser A, Charrel-Dennis M et al (2009) AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458:514–518. https://doi.org/10.1038/nature07725
doi: 10.1038/nature07725 pubmed: 19158675 pmcid: 2726264
Pichlmair A, Schulz O, Tan CP et al (2006) RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314:997–1001. https://doi.org/10.1126/science.1132998
doi: 10.1126/science.1132998 pubmed: 17038589
Yoneyama M, Kikuchi M, Matsumoto K et al (2005) Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 175:2851–2858. https://doi.org/10.4049/jimmunol.175.5.2851
doi: 10.4049/jimmunol.175.5.2851 pubmed: 16116171
Schoggins JW, Wilson SJ, Panis M et al (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481–485. https://doi.org/10.1038/nature09907
doi: 10.1038/nature09907 pubmed: 21478870 pmcid: 3409588
Loo YM, Gale M Jr (2011) Immune signaling by RIG-I-like receptors. Immunity 34:680–692. https://doi.org/10.1016/j.immuni.2011.05.003
doi: 10.1016/j.immuni.2011.05.003 pubmed: 21616437 pmcid: 3177755
Kleinberg J (2003) Bursty and hierarchical structure in streams. Data Min Knowl Discov 7:373–397. https://doi.org/10.1023/A:1024940629314
doi: 10.1023/A:1024940629314
Kato H, Sato S, Yoneyama M et al (2005) Cell type-specific involvement of RIG-I in antiviral response. Immunity 23:19–28. https://doi.org/10.1016/j.immuni.2005.04.010
doi: 10.1016/j.immuni.2005.04.010 pubmed: 16039576
Yoneyama M, Kikuchi M, Natsukawa T et al (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5:730–737. https://doi.org/10.1038/ni1087
doi: 10.1038/ni1087 pubmed: 15208624
Rehwinkel J, Gack MU (2020) RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol 20:537–551. https://doi.org/10.1038/s41577-020-0288-3
doi: 10.1038/s41577-020-0288-3 pubmed: 32203325 pmcid: 7094958
Tsuji H, Nakashima R, Hosono Y et al (2020) Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 72:488–498. https://doi.org/10.1002/art.41105
doi: 10.1002/art.41105 pubmed: 31524333
Lundberg IE, Tjarnlund A, Bottai M et al (2017) 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol 69:2271–2282. https://doi.org/10.1002/art.40320
doi: 10.1002/art.40320 pubmed: 29106061 pmcid: 5846474
Dias Junior AG, Sampaio NG, Rehwinkel J (2019) A balancing act: MDA5 in antiviral immunity and autoinflammation. Trends Microbiol 27:75–85. https://doi.org/10.1016/j.tim.2018.08.007
doi: 10.1016/j.tim.2018.08.007 pubmed: 30201512
Wu B, Peisley A, Richards C et al (2013) Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5. Cell 152:276–289. https://doi.org/10.1016/j.cell.2012.11.048
doi: 10.1016/j.cell.2012.11.048 pubmed: 23273991
Pichlmair A, Schulz O, Tan CP et al (2009) Activation of MDA5 requires higher-order RNA structures generated during virus infection. J Virol 83:10761–10769. https://doi.org/10.1128/JVI.00770-09
doi: 10.1128/JVI.00770-09 pubmed: 19656871 pmcid: 2753146
Halilu F, Christopher-Stine L (2022) Myositis-specific antibodies: overview and clinical utilization. Rheumatol Immunol Res 3:1–10. https://doi.org/10.2478/rir-2022-0001
doi: 10.2478/rir-2022-0001 pubmed: 36467022 pmcid: 9524809
Lundberg IE, Fujimoto M, Vencovsky J et al (2021) Idiopathic inflammatory myopathies. Nat Rev Dis Primers 7:86. https://doi.org/10.1038/s41572-021-00321-x
doi: 10.1038/s41572-021-00321-x pubmed: 34857798
Sato S, Hirakata M, Kuwana M et al (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52:1571–1576. https://doi.org/10.1002/art.21023
doi: 10.1002/art.21023 pubmed: 15880816
Lin JM, Zhang YB, Peng QL et al (2017) Genetic association of HLA-DRB1 multiple polymorphisms with dermatomyositis in Chinese population. Hla 90:354–359. https://doi.org/10.1111/tan.13171
doi: 10.1111/tan.13171 pubmed: 29106035
Gono T, Kawaguchi Y, Kuwana M et al (2012) Brief report: association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum 64:3736–3740. https://doi.org/10.1002/art.34657
doi: 10.1002/art.34657 pubmed: 22886382
Kochi Y, Kamatani Y, Kondo Y et al (2018) Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis 77:602–611. https://doi.org/10.1136/annrheumdis-2017-212149
doi: 10.1136/annrheumdis-2017-212149 pubmed: 29331962
Theisen DJ, Davidson JT, Briseno CG et al (2018) WDFY4 is required for cross-presentation in response to viral and tumor antigens. Science 362:694-+. https://doi.org/10.1126/science.aat5030
Nishina N, Sato S, Masui K et al (2020) Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open 6. https://doi.org/10.1136/rmdopen-2020-001202
Hu H, Yang H, Liu Y et al (2021) Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on type I interferon system. Front Med (Lausanne) 8:833114. https://doi.org/10.3389/fmed.2021.833114
doi: 10.3389/fmed.2021.833114 pubmed: 35141258
He C, Chen J, Luo X et al (2021) Evaluation of biomarkers related to endothelial dysfunction: proof of vasculopathy in anti-melanoma differentiation-associated gene 5 dermatomyositis. Clin Exp Rheumatol 39:151–157. https://doi.org/10.55563/clinexprheumatol/ubov8b
doi: 10.55563/clinexprheumatol/ubov8b pubmed: 32896243
Wenzel J, Schmidt R, Proelss J et al (2006) Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 31:576–582. https://doi.org/10.1111/j.1365-2230.2006.02150.x
doi: 10.1111/j.1365-2230.2006.02150.x pubmed: 16716166
Takada T, Aoki A, Asakawa K et al (2015) Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis. Respir Med 109:1174–1180. https://doi.org/10.1016/j.rmed.2015.07.004
doi: 10.1016/j.rmed.2015.07.004 pubmed: 26187000
Ishida Y, Kimura A, Nosaka M et al (2017) Essential involvement of the CX3CL1-CX3CR1 axis in bleomycin-induced pulmonary fibrosis via regulation of fibrocyte and M2 macrophage migration. Sci Rep 7:16833. https://doi.org/10.1038/s41598-017-17007-8
doi: 10.1038/s41598-017-17007-8 pubmed: 29203799 pmcid: 5714949
Wang Y, Du G, Zhang G et al (2022) Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future. Ann Rheum Dis 81:e192. https://doi.org/10.1136/annrheumdis-2020-218594
doi: 10.1136/annrheumdis-2020-218594 pubmed: 32759260
Bojkova D, Bechtel M, Rothenburger T et al (2023) Omicron-induced interferon signaling prevents influenza A H1N1 and H5N1 virus infection. J Med Virol 95:e28686. https://doi.org/10.1002/jmv.28686
doi: 10.1002/jmv.28686 pubmed: 36938992
Wang G, Wang Q, Wang Y et al (2021) Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study. Front Immunol 12:791348. https://doi.org/10.3389/fimmu.2021.791348
doi: 10.3389/fimmu.2021.791348 pubmed: 34987516 pmcid: 8720853
Coutant F, Bachet R, Pin JJ et al (2022) Monoclonal antibodies from B cells of patients with anti-MDA5 antibody-positive dermatomyositis directly stimulate interferon gamma production. J Autoimmun 130:102831. https://doi.org/10.1016/j.jaut.2022.102831
doi: 10.1016/j.jaut.2022.102831 pubmed: 35436746
Ishikawa Y, Iwata S, Hanami K et al (2018) Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. Arthritis Res Ther 20:240. https://doi.org/10.1186/s13075-018-1737-2
doi: 10.1186/s13075-018-1737-2 pubmed: 30367666 pmcid: 6235206
Allenbach Y, Uzunhan Y, Toquet S et al (2020) Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology 95:e70–ee8. https://doi.org/10.1212/WNL.0000000000009727
doi: 10.1212/WNL.0000000000009727 pubmed: 32487712 pmcid: 7371381
Lv X, Jin Y, Zhang D et al (2021) Low circulating monocytes is in parallel with lymphopenia which predicts poor outcome in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated interstitial lung disease. Front Med (Lausanne) 8:808875. https://doi.org/10.3389/fmed.2021.808875
doi: 10.3389/fmed.2021.808875 pubmed: 35111785
Xu W, Wu W, Zheng Y et al (2021) A computed tomography radiomics-based prediction model on interstitial lung disease in anti-MDA5-positive dermatomyositis. Front Med (Lausanne) 8:768052. https://doi.org/10.3389/fmed.2021.768052
doi: 10.3389/fmed.2021.768052 pubmed: 34912828
Ouyang ZM, Lin JZ, Tang AJ et al (2022) A matrix prediction model for the 6-month mortality risk in patients with anti-melanoma differentiation-associated protein-5-positive dermatomyositis. Front Med (Lausanne) 9:860798. https://doi.org/10.3389/fmed.2022.860798
doi: 10.3389/fmed.2022.860798 pubmed: 35433730
Ida T, Furuta S, Takayama A et al (2023) Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD Open 9. https://doi.org/10.1136/rmdopen-2022-002795

Auteurs

Xueting Yuan (X)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, China.
State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.

Jia Shi (J)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, China.
State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.

Zhao Peng (Z)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, China.
State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.

Liying Peng (L)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, China.
State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.

Shuang Zhou (S)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, China.
State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.

Chanyuan Wu (C)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, China.
State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.

Jiuliang Zhao (J)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, China.
State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.

Dong Xu (D)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, China.
State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.

Mengtao Li (M)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, China.
State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China.

Qian Wang (Q)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China. wangqian_pumch@126.com.
National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, China. wangqian_pumch@126.com.
State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China. wangqian_pumch@126.com.
State Key Laboratory of Common Mechanism Research for Major Diseases, Beijing, China. wangqian_pumch@126.com.

Xiaofeng Zeng (X)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China. zengxfpumc@163.com.
National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, China. zengxfpumc@163.com.
State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China. zengxfpumc@163.com.
State Key Laboratory of Common Mechanism Research for Major Diseases, Beijing, China. zengxfpumc@163.com.

Classifications MeSH